{"id":"h02-chop","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CHOP is a standard polychemotherapy regimen where each agent targets different aspects of cancer cell survival: cyclophosphamide and doxorubicin cause DNA damage, vincristine disrupts microtubule formation to prevent mitosis, and prednisone provides immunosuppression and anti-inflammatory effects. The H02 component likely refers to an additional agent or modification, though the exact composition is not clearly defined in available literature.","oneSentence":"H02+CHOP is a chemotherapy combination regimen that uses doxorubicin, cyclophosphamide, vincristine, and prednisone to inhibit cancer cell proliferation and induce apoptosis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:50.119Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphoma (likely non-Hodgkin lymphoma or Hodgkin lymphoma based on CHOP standard use)"}]},"trialDetails":[{"nctId":"NCT05040906","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients","status":"UNKNOWN","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2020-10-13","conditions":"Recruiting","enrollment":416}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"H02+CHOP","genericName":"H02+CHOP","companyName":"Shandong New Time Pharmaceutical Co., LTD","companyId":"shandong-new-time-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"H02+CHOP is a chemotherapy combination regimen that uses doxorubicin, cyclophosphamide, vincristine, and prednisone to inhibit cancer cell proliferation and induce apoptosis. Used for Lymphoma (likely non-Hodgkin lymphoma or Hodgkin lymphoma based on CHOP standard use).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}